Volume 141, Issue 5, Pages 1656-1664 (November 2011) Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks  Christoph Sarrazin, Susanne Schwendy, Bernd Möller, Nektarios Dikopoulos, Peter Buggisch, Jens Encke, Gerlinde Teuber, Tobias Goeser, Robert Thimme, Hartwig Klinker, Wulf O. Boecher, Ewert Schulte–Frohlinde, Renate Prinzing, Eva Herrmann, Stefan Zeuzem, Thomas Berg  Gastroenterology  Volume 141, Issue 5, Pages 1656-1664 (November 2011) DOI: 10.1053/j.gastro.2011.07.019 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 Trial profile diagram. Therapy completed does not include virologic nonresponders who stopped treatment at week 12 and week 30. Therapy failure includes documented nonresponders and patients with viral breakthrough. Gastroenterology 2011 141, 1656-1664DOI: (10.1053/j.gastro.2011.07.019) Copyright © 2011 AGA Institute Terms and Conditions

Figure 2 Patients in the individualized group (n = 398) received a highly individualized tailored treatment duration ranging from 24 to 72 weeks. Treatment duration was calculated by the baseline HCV RNA viral load (cutoff, 800,000 IU/mL) and the time point at which HCV RNA levels became undetectable for the first time as defined by TMA assay (detection limit, 5–10 IU/mL). Gastroenterology 2011 141, 1656-1664DOI: (10.1053/j.gastro.2011.07.019) Copyright © 2011 AGA Institute Terms and Conditions

Figure 3 Correlation of IL28B genotype with SVR in (A) all patients at baseline and (B) patients who achieved undetectable HCV RNA levels at least one time during therapy (virologic on-treatment response). Virologic relapse according to IL28B genotype in the per-protocol population in patients with (C) low baseline viral load and (D) high baseline viral load. Gastroenterology 2011 141, 1656-1664DOI: (10.1053/j.gastro.2011.07.019) Copyright © 2011 AGA Institute Terms and Conditions